Pregnancy: Sodium Valproate

Department of Health and Social Care written question – answered on 1st May 2019.

Alert me about debates like this

Photo of Cat Smith Cat Smith Shadow Minister for Voter Engagement and Youth Affairs, Shadow Deputy Leader of the House of Commons

To ask the Secretary of State for Health and Social Care, what assessment he has made of whether the NICE guideline for epilepsy on sodium valproate as first-line treatment for children, young people and adults with newly diagnosed juvenile myoclonic epilepsy is compatible with the Medicines and Healthcare Products Regulatory Agency pregnancy prevention programme.

Photo of Seema Kennedy Seema Kennedy The Parliamentary Under-Secretary for Health and Social Care

The National Institute for Health and Care Excellence (NICE) is an independent body and is responsible for the wording of its guideline recommendations. NICE has advised that it will ensure that its recommendations on the use of sodium valproate are consistent with the regulatory position, as set out by the Medicines and Healthcare products Regulatory Agency. The two organisations are working closely together to ensure that this is the case.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.